Skip to main content
Clinical Trials/NCT00809016
NCT00809016
Completed
Not Applicable

Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors

Centre Oscar Lambret1 site in 1 country40 target enrollmentMay 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
Centre Oscar Lambret
Enrollment
40
Locations
1
Primary Endpoint
Difference between the target volume to be irradiated as measured by conventional imagining and PET
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

RATIONALE: Imaging procedures, such as PET scans, may determine the extent of cancer and help doctors plan radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy that uses a 3-dimensional image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This clinical trial is studying PET scans to see how well they work in patients with head and neck cancer who are undergoing 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy.

Detailed Description

OBJECTIVES: Primary * To assess the value of pre-treatment PET in determining the target volume in patients with head and neck cancer undergoing three-dimensional conformational radiotherapy and intensity-modulated radiotherapy. Secondary * To evaluate variations in weekly fludeoxyglucose F 18 PET imaging during the first 5 weeks of treatment. * To determine the relationship between changes in tumor metabolism during radiotherapy and control tumor at 3 months and at 1 year post-treatment. OUTLINE: This is a multicenter study. Patients undergo fludeoxyglucose F18 PET (FDG-PET) in addition to conventional imaging at baseline. Patients undergo standard three-dimensional conformational radiotherapy and intensity-modulated radiation therapy 5 days a week for 5 weeks. Some patients also undergo weekly FDG-PET during treatment.

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
May 2011
Last Updated
14 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Difference between the target volume to be irradiated as measured by conventional imagining and PET

Study Sites (1)

Loading locations...

Similar Trials